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Abstract
Background: Iron is an essential cofactor in almost all biological systems. The lactic acid bacteria (LAB), frequently employed
as probiotics, are unusual in having little or no requirement for iron. Iron in the human body is sequestered by transferrins
and lactoferrin, limiting bacterial growth. An increase in the availability of iron in the intestine by bleeding, surgery, or under
stress leads to an increase in the growth and virulence of many pathogens. Under these high iron conditions, LAB are
rapidly out-competed; for the levels of probiotic bacteria to be maintained under high iron conditions they must be able to
respond by increasing growth rate to compete with the normal flora. Despite this, iron-responsive genera are poorly
characterised as probiotics.
Methodology/Principal Findings: Here, we show that a panel of probiotics are not able to respond to increased iron
availability, and identify an isolate of Streptococcus thermophilus that can increase growth rate in response to increased iron
availability. The isolate of S. thermophilus selected was able to reduce epithelial cell death as well as NF-kB signalling and IL-
8 production triggered by pathogens. It was capable of crossing an epithelial cell barrier in conjunction with E. coli and
downregulating Th1 and Th17 responses in primary human intestinal leukocytes.
Conclusions/Significance: We propose that an inability to compete with potential pathogens under conditions of high iron
availability such as stress and trauma may contribute to the lack of efficacy of many LAB-based probiotics in treating
disease. Therefore, we offer an alternative paradigm which considers that probiotics should be able to be competitive
during periods of intestinal bleeding, trauma or stress.
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Introduction
The benefit of consuming specific strains of bacteria was first
proposed by Elie Metchnikoff. He suggested that since lactic acid
bacteria can prevent putrefaction of stored food, they may also
benefit the gastrointestinal tract; Bulgarian bacillus (later identified
as Lactobacillus delbruickii subspecies bulgaricus) isolated from a
fermented milk product was of particular interest. Metchnikoff
proposed it was the optimal strain to consume because of its ability
to produce large amounts of lactic acid with little succinic or acetic
acid; its ability to coagulate milk rapidly; and the lack of alcohol and
acetone produced [1]. Interest in probiotics waned with the advent
of antibiotics. However, with the emergence of antibiotic-resistant
bacteria, there is renewed interest in probiotic bacteria, now defined
as ‘‘live microorganisms which when administered in adequate
amounts confer a health benefit on the host’’ [2]. Following on from
Metchnikoff’s work, candidate probiotics, in particular Lactobacillus
spp., have been trialled in the treatment of a number of diseases.
Some Lactobacillus spp. have been shown to reduce symptoms in
allergic rhinitis [3] and atopic eczema [4,5]. Specifically, L. casei
Shirota may reduce the severity of allergic rhinitis sufferers by
reducing antigen-induced IL-5, IL-6 and IFN-c, as well as specific
IgE [3]. Meanwhile, L. rhamnosus (strain GG ATCC 53103), L.
reuteri (ATCC 55730) and L. paracasei (strain F19) have been shown
to decrease the incidence of eczema in cohorts of children
[6,7,8,9,10].
Lactobacillus spp. have also been successful in the treatment of
acute infectious diarrhoea in children [11] and prevention of
traveller’s diarrhoea [12] and antibiotic-associated diarrhoea
(AAD) [13], but not Crohn’s disease [14]. In contrast, two
probiotic preparations which are not based upon Lactobacillus spp.,
VSL#3 and Escherichia coli Nissle 1917, have shown promise in the
treatment of inflammatory bowel disease (IBD) [15,16,17,18].
Crohn’s disease is considered to be a response to an environmental
trigger in a genetically susceptible host. The environmental trigger
is thought to be bacteria and current research is now focuses on
adherent-invasive E. coli (AIEC) [19]. If Crohn’s disease is
triggered by bacteria then it is an attractive candidate for
treatment with a probiotic which could either outcompete the
bacteria or divert the immune response in order to prevent the
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IBD. However, in order for any organism to carry out either of
these functions it must be able to survive and compete within this
challenging environment.
The lactic acid bacteria (LAB) are unusual organisms in that
they do not appear to have a requirement for iron [20,21,22]
whilst maintaining a high demand for manganese [23]. In the
human body, iron is sequestered by the transferrins and lactoferrin
[24]. Iron sequestration is considered the primary factor limiting
bacterial growth rate in the body. An increase in the availability of
iron in the intestine by dietary supplementation, intestinal
bleeding, surgery, trauma or under stress, will lead to an increase
in the abundance of many bacterial species. This is mediated by a
greater availability of free iron, or by the presence of noradren-
aline, which unloads iron from chelators and can supply it to some
species of bacteria [25,26]. Under these high-iron conditions, LAB
are rapidly outcompeted as other species increase their growth rate
in response to iron availability and predominate. Thus, for the
levels of probiotic bacteria to be maintained under high iron
conditions they must be able to respond to this element by
increasing growth rate in order to compete with the normal flora.
We propose that an inability to compete with potential pathogens
under conditions of stress and trauma may contribute to the lack of
efficacy of many LAB-based preparations in treating disease.
Here, we show that the majority of LAB do not respond to
noradrenaline-mediated iron availability by increasing growth
rate. We have identified species of bacteria that can increase
growth rate under these conditions, and using a rational selection
process we have found an isolate of S. thermophilus with probiotic
potential, based on functionality in in vitro models. We propose an
alternative paradigm to the traditional LAB spp. probiotics, which
considers that probiotics should be able to be active and functional
during periods of intestinal bleeding, trauma or stress.
Results
Growth of bacteria with noradrenaline
Noradrenaline can remove iron from chelators and supply it to
bacteria. A number of LAB were cultured with and without
noradrenaline to determine whether they were capable of
responding to it, or the iron provided by it (Table 1). While the
addition of noradrenaline had no effect on most LAB studied, two
strains significantly increased their growth in response to it: L.
acidophilus ASF360 increased its growth more than 7-fold at
48 hours and S. thermophilus NCIMB 41856 increased growth at all
time points studied, with a maximum of an almost 5-fold increase
at 48 hours (Table 1). These two strains were chosen for further
characterisation of their probiotic potential, alongside E. coli Nissle
1917 which has been used for the treatment of IBD [15].
Proliferation and death of epithelial cells
Increased turnover of epithelial cells is a common response to
infection therefore T84 and Caco-2 adenocarcinoma cells were
incubated with the potential probiotics L. acidophilus ASF360, S.
thermophilus NCIMB 41856 and E. coli Nissle 1917 to determine
their effect on the proliferative or apoptotic cellular response to
pathogenic E. coli strains, K12 and the Crohn’s disease-associated
AIEC strain HM615 [27]. All E. coli strains, including E. coli Nissle
1917, reduced the proliferation of T84 epithelial cells: E. coli K12
reduced proliferation by 78% compared to untreated cells
(p=0.002); AIEC HM615 reduced proliferation by 80%
(p=0.0001); and E. coli Nissle 1917 by 82% (p=0.001)
(Figure 1A). A similar reduction in proliferation of Caco-2 cells
was seen following E. coli treatment: E. coli K12 induced a
reduction of 77% compared to untreated cells (p=0.003); AIEC
HM615 induced a reduction of 76% (p=0.003); and E. coli Nissle
1917 of 78% (p=0.004) (Figure 1C). Simultaneously, cell death
was increased in both T84 and Caco-2 cells; E. coli K12 induced a
254% increase in cell death in Caco-2 cells (p=0.0005); AIEC
HM615 induced a 498% increase in death in T84 cells
(p=0.0003) and a 254% increase in Caco-2 cell death
(p=0.001); E. coli Nissle 1917 induced a 498% increase in T84
cell death (p,0.0001) and a 218% increase in Caco-2 cell death
(p=0.001) (Figure 1D). S. thermophilus NCIMB 41856 reduced the
proliferation of Caco-2 cells treated with E. coli K12 or AIEC
HM615 by 35% (p=0.003) and 31% (p=0.05), respectively; while
E. coli Nissle 1917 reduced proliferation induced by E. coli K12 by
32% (p=0.007) and 37% in response to AIEC HM615 treatment
(p=0.03) (Figure 1B). In addition, L. acidophilus ASF360 further
reduced proliferation of Caco-2 cells treated with AIEC HM615
by 22% (p=0.02) (Figure 1B). S. thermophilus NCIMB 41856
reduced proliferation of T84 cells treated with AIEC HM615 and
E. coli Nissle 1917 by 33% (p=0.03) and 48% (p=0.03),
respectively (Figure 1A). Importantly, all three probiotic strains
reduced death of Caco-2 cells following challenge with both E. coli
K12 and HM615: L. acidophilus ASF360 reduced death of epithelial
cells by 14% (p=0.04) following E. coli K12 treatment and 16%
following infection with AIEC HM615 (p=0.03); S. thermophilus
NCIMB 41856 reduced death of epithelial cells following E. coli
K12 and AIEC HM615 treatment by 10% (p=0.01) and 18%
(p=0.007), respectively; E. coli Nissle 1917 reduced death of
epithelial cells following E. coli K12 and treatment by 26%
(p=0.006) and 27% (p=0.003), respectively (Figure 1D). In
addition, S. thermophilus NCIMB 41856 was able to reduce
proliferation and cell death of untreated Caco-2 cells by 24%
(p=0.008) and 22% (p=0.02) respectively (Figure 1B and D).
Induction of NF-kB and IL-8
Monolayers of Caco-2 and T84 cells were treated with the three
potential probiotic bacterial strains in combination with patho-
genic E. coli strains in order to determine the effect of probiotic on
either of these pro-inflammatory signalling events. NF-kB
signalling in Caco-2 cells was upregulated by 491% (p=0.002)
compared to controls following infection with E. coli K12 and by
247% (p=0.002) following AIEC HM427 treatment. However,
this induction was reduced by the addition of all three probiotic
strains: L. acidophilus ASF360 reduced the NF-kB response to E. coli
Table 1. Response of lactic acid bacteria to noradrenaline.
24 Hours 48 Hours 72 Hours
L. bulgaricus JB005 1.22760.215 1.32860.279 1.26660.125
L. casei JB006 0.84860.144 1.19160.180 1.44060.017
L. casei JB008 1.14060.074 1.03560.125 1.35760.446
L. acidophilus ASF360 1.28560.179 7.72562.519 * 2.37560.937
L. salivarius ASF361 1.02160.128 0.86560.175 1.18760.173
L. plantarum JB012 1.01460.170 0.94360.115 1.11260.250
L. helveticus JB011 0.99960.114 1.00360.097 1.00460.214
B. animalis JB007 0.99860.313 1.24660.398 1.03760.326
B. bifidum JB009 1.17560.134 1.20960.172 1.19060.169
S. thermophilus JB004 0.98660.296 1.37460.109 1.57660.439
S. thermophilus NCIMB
41856
1.70060.242 * 4.79860.868 * 3.86961.954 *
*Indicates p#0.05 when compared to the mean value for each time point.
doi:10.1371/journal.pone.0026507.t001
Iron Responsive Candidate Probiotic
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thermophilus NCIMB 41856 reduced the NF-kB response to E. coli
K12 by 58% (p=0.002) and AIEC HM427 by 49% (p=0.005);
and E. coli Nissle 1917 reduced the NF-kB response to E. coli K12
by 79% (p=0.0005) and AIEC HM427 by 68% (p=0.004)
(Figure 2A). S. thermophilus NCIMB 41856 also reduced NF-kB
signalling by 48% in untreated cells (p=0.003) (Figure 2A).
Following NF-kB signalling, IL-8 production was increased by
1566% in response to E. coli K12 (p=0.001), 1104% in response
to AIEC HM427 (p=0.004) and 363% in response to HM615
(p=0.02), as well as a 1498% increase following addition of E. coli
Nissle 1917 (p=0.004). The IL-8 response to E. coli K12 was
reduced by 22% following addition of S. thermophilus NCIMB
41856 (p=0.02) and the response to AIEC HM427 was reduced
by both L. acidophilus ASF360 and S. thermophilus NCIMB 41856 by
17% (p=0.02) and 39% (p=0.02) respectively (Figure 2B).
Maintenance of epithelial barrier integrity
To determine the effect of our probiotic strains on epithelial
barrier integrity, Caco-2 and T84 cells were grown in a Transwell
system and challenged with E. coli K12 or AIEC HM615 in
combination with each of the potential probiotics; TEER and
bacterial translocation were measured. Both Caco-2 and T84 cells
formed stable monolayers after 8–10 days. Neither L. acidophilus
ASF360 nor S. thermophilus NCIMB 41856 had any effect on
TEER alone. However, S. thermophilus NCIMB 41856 blocked the
passage of E. coli K12 through the monolayer, a phenomenon not
seen with L. acidophilus ASF360 which enhanced the passage of E.
coli K12 across the barrier (Figure 3). In addition, S. thermophilus
NCIMB 41856 reduced the response to E. coli K12, by increasing
TEER, in a way that L. acidophilus ASF360 did not; when S.
thermophilus NCIMB 41856 and E. coli K12 were added to the
monolayer simultaneously, an increase in TEER was seen (peaking
at 33% in Caco-2 cells at 6 hours and 30% in T84 cells at
10 hours compared to K12 stimulated cells), whereas L. acidophilus
ASF360 and E. coli K12 together caused a decrease in TEER
(peaking at 56% in Caco-2 cells at 8 hours and 11% in T84 cells at
6 hours compared to K12 stimulated cells) (Figure S1). While
AIEC HM615 alone slowly migrated through the monolayer, both
L. acidophilus ASF360 and S. thermophilus NCIMB 41856 appeared
to interact with this strain and facilitate its migration across the
epithelial monolayer. In this situation, translocation of L. acidophilus
ASF360 and S. thermophilus NCIMB 41856 was increased until
these probiotic strains were present in equal numbers to the
pathogenic strain (Figure 3). The potentially probiotic E. coli strain
Nissle 1917, similarly to L. acidophilus ASF360 and S. thermophilus
Figure 1. Probiotic effect on proliferation and death of epithelial cells in response to pathogenic E. coli. A) Proliferation of T84 cells; B)
proliferation of Caco-2 cells; C) death of T84 cells; D) death of Caco-2 cells. Results are shown from 3 replicate experiments and are expressed as mean
+ S.E.M. * p#0.05, ** p#0.01 and *** p#0.001.
doi:10.1371/journal.pone.0026507.g001
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to translocate quickly without the need to interact with pathogenic
E. coli strains (Figure 3).
Maintenance of tight cell junctions
Caco-2 and T84 cells were grown in a Transwell system and
infected with AIEC HM615; S. thermophilus NCIMB 41856 was
Figure 3. Translocation of bacteria through a T84 (A) or Caco-2 (B) epithelial cell monolayer. Results are shown from 3 replicates and are
expressed as means. * p#0.05, ** p#0.01 and *** p#0.001.
doi:10.1371/journal.pone.0026507.g003
Figure 2. Effect of probiotics on NF-kB (A) and IL-8 (B) response to pathogen. Results are shown from 6 replicate experiments and are
expressed as mean + S.E.M. * p#0.05, ** p#0.01 and *** p#0.001.
doi:10.1371/journal.pone.0026507.g002
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occludin. AIEC HM615 caused the breakdown of tight cell
junctions in Caco-2 and T84 monolayers, illustrated by decreased
occludin (61% and 56% respectively) (Figure 4). AIEC HM615
also caused a 24% decrease in nuclear staining of T84 cells (data
not shown), indicating that it was inducing cell death. The addition
of S. thermophilus NCIMB 41856 to the monolayers in conjunction
with AIEC HM615 prevented AIEC-induced tight cell junction
breakdown and cell death; levels of nuclear and occludin staining
were unchanged from control monolayers (Figure 4).
Skewing of effector T cell responses
Leukocytes were isolated from the intestinal lamina propria and
challenged with bacterial antigens from E. coli K12 and AIEC
HM615 to determine the effect of competing probiotic antigens
from L. acidophilus ASF360, S. thermophilus NCIMB 41856 and E.
coli Nissle 1917. Both E. coli K12 and AIEC HM615 induced a
Th1 response, indicated by upregulation of mRNA encoding the
Th1-specific transcription factor T-box21 in the population of
cultured leukocytes (16% (p=0.003) and 13% (p=0.007)
respectively); this was significantly reduced by the addition of L.
acidophilus ASF360 or S. thermophilus NCIMB 41856. L. acidophilus
ASF360 reduced the response to E. coli K12 and AIEC HM615 by
13% (p=0.003) and 11% (p=0.02), respectively. S. thermophilus
NCIMB 41856 reduced the Th1 response to E. coli K12 and AIEC
HM615 by 10% (p=0.03) and 13% (p=0.04), respectively. E. coli
Nissle 1917 also downregulated the Th1 response to AIEC
HM615 by 21% (p=0.009). Furthermore, S. thermophilus NCIMB
41856 reduced the baseline level of transcription of T-box21 in
untreated cells by 6% (p=0.03). Neither E. coli strain induced a
significant Th2 response but the Th17-specific transcription factor,
RORC, was also upregulated following treatment with E. coli K12
or AIEC HM615 antigens (9% and 13% (p=0.02), respectively).
The Th17 response to E. coli K12 was reduced by 12% following
the addition of L. acidophilus ASF360 antigens (p=0.009) and the
response to AIEC HM615 was reduced by the addition of any of
the three potential probiotic strains: L. acidophilus ASF360 reduced
the response by 18% (p=0.0002), S. thermophilus NCIMB 41856 by
15% (p=0.003) and E. coli Nissle 1917 by 26% (p=0.003). In
addition, both L. acidophilus ASF360 and S. thermophilus NCIMB
41856 were capable of reducing the baseline level of RORC
transcription in untreated cells by 10% (p=0.003 and p=0.04,
respectively). AIEC HM615 also induced a strong Treg response,
shown by the upregulation of Foxp3 by 30% (p=0.0009) in
cultured leukocytes. However, this was reduced by the addition of
any of the three potential probiotic strains: L. acidophilus ASF360
caused an 18% reduction in Foxp3 expression (p=0.02), S.
thermophilus NCIMB 41856 a 21% reduction (p=0.03) and E. coli
Nissle 1917 a 27% reduction (p=0.02) (Figure 5A).
T cell cytokine production
In accordance with the transcription factor data previously
described, both E. coli K12 and AIEC HM615 induced
upregulation of TNFa mRNA in cultured leukocyte populations
(9% and 12% respectively), indicating a Th1 response. Despite
this, neither E. coli K12 or AIEC HM615 induced a significant
Figure 4. Maintenance of tight cell junctions by probiotics. Expression of occudin (red) in epithelial cell monolayers (A). Proportion of pixels
positive for occludin staining relative to entire field of view in T84 (B) and Caco-2 cells (C). Results are expressed as mean+S.E.M. * p#0.05 and
** p#0.01.
doi:10.1371/journal.pone.0026507.g004
Iron Responsive Candidate Probiotic
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by 15% when E. coli K12 and Nissle 1917 were used in
combination (p=0.04) and decreased by 16% following treat-
ment with L. acidophilus ASF360 (p=0.01) or by 10% following
treatment with S. thermophilus NCIMB 41856 (p=0.02) alone. The
TNFa response to E. coli K12 was reduced by 16% by the
addition of L. acidophilus ASF360 (p=0.03) whereas S. thermophilus
NCIMB 41856 reduced the level of TNFa mRNA produced in
response to AIEC HM615 by 20% (p=0.03) (Figure 5B). As
expected, there was no significant change in the production of the
Th2-related cytokine IL-4. Although not significant, both E. coli
strains appeared to increase the expression of IL-4d2 mRNA, the
naturally occurring antagonist of IL-4, further indicating skewing
towards a Th1 response. However, evidence for a Th17 response
was seen in the increased expression of IL-17 mRNA by 45%
(p=0.04) following treatment with antigens derived from AIEC
HM615; this appeared to be reduced by the addition of any of
the three probiotic strains, although this was not statistically
significant. No significant changes were seen in the expression of
IL-10 mRNA, although E. coli Nissle 1917 did reduce IL-10
expression by 29% when cultured in combination with AIEC
HM615; however HM615 did not induce the expression of IL-10
(Figure S2). The transcription of TGFb was significantly
increased by lamina propria leukocytes by 14% in response to
E. coli K12 (p=0.01) and by 11% in response to AIEC HM615
(p=0.009) treatment. L. acidophilus ASF360 and S. thermophilus
NCIMB 41856 were able to reduce the induction of TGFb
mRNA by E. coli K12 by 12% (p=0.01) and 9% (p=0.006) to
levels comparable to that of control cells. Similarly, L. acidophilus
ASF360 and S. thermophilus NCIMB 41856 also reduced the
TGFb response to AIEC HM615 by 12% (p=0.04) and 10%
(p=0.009) respectively. E. coli Nissle 1917 was also able to reduce
the expression of TGFb mRNA induced by AIEC HM615 by
23% (p=0.01) (Figure 5B).
Discussion
The mechanisms through which probiotics have been hypothe-
sised to act are numerous and include an influence on intestinal
transit time, competition with pathogens and immunomodulation.
It is not clear what effect on the immune system is most desirable.
A pro-inflammatory response may be required in order to more
effectively clear infection [28,29], however prolonged NF-kB
activation, and subsequent production of IL-8, RANTES and
CXCL10, has been implicated in animal models of IBD [30]. In
contrast some strains of bacteria have been shown to act
specifically on components of the adaptive immune response in
order to reduce inflammation and promote regulation. Faecalibac-
terium prausnitzii A2–165 (DSM 17677) is capable of reducing the
expression of the pro-inflammatory cytokines IL-12 and IFNc by
PBMCs [31]. Upregulation of regulatory IELs in a mouse model
of colitis was induced by two mixtures of probiotics: L. acidophilus
Bar 13 and B. longum Bar 33; L. plantarum Bar 10, S. thermophilus Bar
20 and B. animalis subsp. lactis Bar 30 [32]. Furthermore, a
combination of L. acidophilus, L. casei, L. reuteri, B. bifidum and S.
thermophilus downregulated Th1, Th2 and Th17 cytokine respons-
es, induced generation of CD4
+ Foxp3
+ Tregs and promoted
regulatory dendritic cells expressing high levels of the regulatory
cytokines IL-10 and TGFb [33].
LAB have uniquely very low requirements for iron [20,21,22].
The increased bioavailability of iron during intestinal bleeding can
increase the growth rate and virulence of many gastrointestinal
pathogens [34]; under these conditions, LAB can be outcompeted.
The results of this work indicate that most LAB cannot respond to
increased iron bioavailability (Table 1), with the exception of
Lactobacillus acidophilus ASF360 and Strep. thermophilus NCIMB
41856. One of the principal mechanisms for the action of
probiotics is thought to be competitive exclusion of pathogens.
These results support the theory that LAB are inefficient during
active inflammatory disease because of their inability to compete
Figure 5. Effect of probiotics on the adaptive immune response. Percent change in expression of T-box21 (Th1), RORC (Th17) and Foxp3
(Treg) transcription factor mRNA in response to E. coli and the effect of probiotics on their expression (A). Percent change in cytokine mRNA levels
induced by T cells in response to E. coli with and without probiotic (B). Results are expressed as mean6S.E.M. * p#0.05 and ** p#0.01.
doi:10.1371/journal.pone.0026507.g005
Iron Responsive Candidate Probiotic
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supplementation.
For a probiotic to be effective in treating IBD, we consider that
it must be able to effectively compete with pathogens under
conditions encountered in the non-healthy intestine. It should also
be able to control immune responses to pathogens and restore
normality. These are the primary properties that we investigated
in this work. Using a rational selection process we have
determined that the iron-responsive strain of S. thermophilus
NCIMB 41856 shows probiotic potential. This S. thermophilus
NCIMB 41856 performed at least as well, and in many cases,
better than, the more widely researched strains of L. acidophilus and
E. coli Nissle 1917. L. acidophilus ASF360 showed a growth increase
in response to iron, but only after 48 h, with the increase not being
sustained after 72 h. In order for an organism to be able to
establish itself and compete against pathogens in an iron-rich
environment, stimulation of growth should ideally occur within
typical intestinal transit time and then be sustained. This organism
did not meet this test. In contrast, E. coli is known to be able to
respond to iron in this manner [34], as is S. thermophilus NCIMB
41856 (Table 1); however, whereas S. thermophilus NCIMB 41856
promoted an anti-inflammatory response, E. coli Nissle 1917
provoked a pro-inflammatory response, consistent with the
findings of other groups [35]. It has been hypothesised that
activation of epithelial cells, as demonstrated here by the ability of
E. coli Nissle 1917 to induce an NF-kB and IL-8 response, leads to
an increase in innate immune defences, thereby improving barrier
function [36]. However, concerns have been raised about the
safety of E. coli Nissle 1917 as a probiotic, particularly in
immunocompromised patients [37].
The results presented here show that our strain of S. thermophilus
NCIMB 41856 appears to be a promising candidate as a probiotic,
at least in our in vitro experiments. S. thermophilus has largely been
overlooked as a probiotic strain of bacteria in favour of Lactobacillus
or Bifidobacterium spp and little work has been done to determine its
mode of action. Despite this, it is a constituent of the VSL#3
probiotic preparation, one of the few probiotic therapies to have a
significant effect on the treatment of IBD [18]. S. thermophilus is also
present in the majority of fermented milk products, some of which
have been successfully used as therapeutic treatments [38];
however the levels of bacteria are too low to have a probiotic
effect [39]. We have found that the beneficial effect exerted by S.
thermophilus NCIMB 41856 is dose-dependent, with the optimum
dose being 1000 times more concentrated than that found in the
majority of fermented milk products previously trialled. Few
studies have looked into the probiotic effect of S. thermophilus alone,
however, it was reported that milk fermented with this strain of
bacteria was equivalent to proton-pump inhibitors in reducing
gastritis induced by non-steroidal anti-inflammatory drugs [40].
We propose that the predominant effect of S. thermophilus
NCIMB 41856 would be in limiting the pro-inflammatory
response initiated by the innate immune system. Furthermore, it
acts on the adaptive immune system by modulating the T cell
response, promoting regulation and reducing inflammation. The
pro-inflammatory response to pathogenic E. coli was essentially
cancelled out by the addition of S. thermophilus NCIMB 41856,
returning levels of the varying T cell subsets to those seen under
normal conditions in our ex vivo system. This was further
emphasised by the ability of S. thermophilus NCIMB 41856 to
reduce the transcription of mRNA encoding TNFa in response to
AIEC. As previously mentioned, AIEC has been implicated in the
pathogenesis of Crohn’s disease, therefore the ability of S.
thermophilus NCIMB 41856 to reduce the production of TNFa,
the principle pro-inflammatory cytokine present in this condition,
is highly important and warrants further investigation; inflamma-
tion-induced fibrosis leading to stricture formation in Crohn’s
disease represents a serious complication with important clinical
implications [41]. reducing inflammation, firstly exerting its effects
from the lumen of the gut and secondly, when intestinal barrier
function is compromised, by crossing through the epithelium and
interacting with the underlying cells. Here we have shown that this
bacterium is capable of reducing epithelial cell death as well as the
NF-kB and IL-8 response to pathogen, thereby.
In conclusion, S. thermophilus NCIMB 41856 is an iron-
responsive probiotic strain of bacteria with far-reaching applica-
tions, capable of reducing egress of pathogenic bacteria from the
lumen of the gut, improving barrier function and reducing
inflammation. Clinical evaluation is now needed to determine




Tissue was collected from patients after written informed
written consent and with appropriate ethical approval from the
Somerset Research Ethics Committee.
Bacteria used
Species of lactic acid bacteria that have been employed as
probiotics were used. These were: L. bulgaricus JB005, L. casei
JB006, L. casei JB008, B. animalis JB007, and B. bifidum JB009
(isolated from yoghurt); L. plantarum JB012 and L. helveticus JB012
(isolated from probiotic capsules); and the commensal isolates L.
acidophilus ASF360 and L. salivarius ASF361 (components of the
Schaedler flora). Two strains of S. thermophilus (JB004 and NCIMB
41856) were isolated from yoghurt. Two strains of AIEC were
used: HM427 and HM615 (kindly provided by Dr Barry
Campbell and Prof Jon Rhodes, University of Liverpool), as was
E. coli K12 and E. coli Nissle 1917 (isolated from Mutaflor
(Ardeypharm GmbH, Herdecke, Germany)). All E. coli strains
were grown in 10 ml volumes of LB broth (Oxoid, Cambridge,
UK) at 37uC overnight. S. thermophilus was grown in M17 broth
supplemented with lactose (Oxoid) and Lactobacillus spp were
cultured in MRS broth (Oxoid) overnight in a microaerobic
atmosphere. Lactic acid bacteria were cultured in serum-SAPI
medium with and without 100 mM (-) noradrenaline (Sigma,
Poole, UK) in order to determine if they were capable of
responding to it. O.D. measurements were taken at 24, 48 and
72 hours in order to determine bacterial growth. Differences were
analysed using a repeated-measures ANOVA.
Proliferation and death of epithelial cells
All cell culture reagents were purchased from PAA Laboratories
(Austria) unless otherwise specified. T84 and Caco-2 human
adenocarcinoma cells (ECACC, Health Protection Agency
Culture Collection, Salisbury, UK) were grown in DMEM/Ham’s
F-12 or DMEM respectively, supplemented with 10% FCS, 2 mM
L-glutamine and 100 U/ml penicillin/streptomycin in 96-well
tissue culture plates at an initial density of 2.4610
4 cells per well.
After 3 days incubation, the medium was changed for one that was
antibiotic-free and cells were labelled with BrdU in order to
quantify proliferation. Bacteria were added to the epithelial cell
cultures at an MOI of 30 and incubated for 24 hours at 37uC with
5% CO2. After 24 hours supernatants were harvested to
determine cytotoxic effects of bacteria using the Cytotox 96 non-
radioactive cytotoxicity assay kit (Promega, Southampton, UK) as
directed by the manufacturer’s instructions. Quantification of
Iron Responsive Candidate Probiotic
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proliferation biotrack ELISA system (GE Healthcare, Chalfont St
Giles, UK) as per the manufacturer’s instructions. Differences
were analysed using paired t-tests (GraphPad Prism 5, California,
USA).
NF-kB assays
Caco-2 cells were seeded into 12-well tissue culture plates at an
initial density of 6610
5 cells per well. After 2 days of culture, cells
were transfected with a reporter plasmid having an NF-kB
response element, pGL4.32 (Promega), and the internal control
reporter pGL4.74 (Promega) using lipofectamine (Invitrogen,
California, USA). 24 hours later, the medium was replaced with
1x HBSS (Invitrogen) and bacteria were added at an MOI of 30.
After 40 hours, cells were lysed and luciferase activity was
quantified using a Dual Luciferase Reporter Assay (Promega) as
per the manufacturer’s instructions. Differences were analysed
using paired t-tests (GraphPad Prism 5). T84 cells could not be
efficiently transfected using these reporter plasmids and therefore
results are not shown.
Detection of IL-8
In order to determine the effect of potential probiotic strains on
IL-8 production T84 cells were seeded into 12-well tissue culture
plates at an initial density of 6610
5 cells per well. After 3 days of
culture, the medium was replaced with antibiotic-free medium and
bacteria added at an MOI of 30. After 6 hours supernatants were
harvested. Cytotoxicity was determined as above and production
of IL-8 was quantified by ELISA using the human IL-8/CXCL8
DuoSet (R&D Systems, Minneapolis, USA) as per the manufac-
turer’s instructions. IL-8 production was corrected for cell death
and differences were analysed using paired t-tests (GraphPad
Prism 5). Caco-2 cells did not produce sufficient levels of IL-8 and
therefore results are not shown.
Growth of epithelial cell monolayers and challenge with
bacteria
Caco-2 and T84 cells were seeded onto 12-mm Transwell
membranes (12 mm diameter, 3mm pore size; Corning Glass
Works, Corning, NY) in 12-well tissue culture plates at an initial
density of 3610
5 cells per insert. Plates were incubated at 37uCi n
5% CO2 for 8–10 days until the cells formed confluent monolayers
and the transepithelial resistance (TEER) was greater than 300 V/
cm
2 as measured with an epithelial voltmeter as an indicator of
membrane permeability. The medium was then changed to one
that was antibiotic free and bacteria were added to the apical well
of the Transwell insert at an MOI of 30. TEER of all monolayers
was measured at 2 hour intervals up to 12 hours and bacterial in
the basal well were enumerated every 2 hours up to 10 hours.
Differences were evaluated at each time point using paired t-tests
(GraphPad Prism 5). In a separate experiment, medium was
removed from the Transwells after 10 hours and the monolayers
were examined as detailed below.
Occludin staining
Transwell inserts were fixed in ice-cold methanol at 4uC
overnight. Inserts were washed in PBS and the cells permeabilised
with 0.1% Triton X-100 for 10 minutes before being washed
again. Mouse anti-occludin monoclonal antibody (Zymed, Cali-
fornia, USA) was diluted 1/200 and added to the apical chamber
of the insert and incubated at room temperature for 45 minutes.
Inserts were then washed in PBS and incubated for a further 45
minutes with TRITC-conjugated isotype-specific goat anti-mouse
antibody (Southern Biotech, Birmingham, AL, USA) diluted 1/
100 in the apical chamber. The inserts were then washed with PBS
and the membranes were cut out of the inserts with a scalpel and
mounted on slides with Vectashield containing DAPI (Vector
Laboratories, California, USA). Fluorescent staining was exam-
ined on a Leica DMRA microscope equipped with a Hamamatsu
Orca-ER monochrome camera. Ten fields of view per slide at 40x
magnification were digitised using Leica Q-Fluoro software.
Images were viewed using ImageJ software (http://rsb.info.nih.
gov/ij) and positive pixels automatically counted as previously
described [42]. The significance of differences was determined by
one-way ANOVA (GraphPad Prism 5).
T cell isolation and culture
Resected intestinal tissue was collected from patients undergo-
ing surgery for complications associated with Crohn’s disease or
ulcerative colitis and from patients with colorectal cancer after
informed written consent and with appropriate ethical approval
(Somerset Research Ethics Committee). The mucosa was
separated from the muscle, cut into small fragments and incubated
in collagenase (100 U/ml; Sigma) for 2 hours at 37uC. Cells were
washed in PBS and leukocytes purified over discontinuous Percoll
gradients (35–75%; GE Healthcare). The cell count and viability
was determined by trypan blue exclusion. Cells were resuspended
to a final concentration of 5610
6/ml in RPMI 1640 supplemented
with 10% FCS, 1 mM sodium pyruvate, 2 mM L-glutamine and
50mg/ml gentamicin and cultured on top of a type I collagen gel
(PureCol; Nutacon BV, The Netherlands). It has previously been
shown that co-culture of lamina propria T cells with ECM
components prevents activation-induced apoptosis [43] and, in
particular, ligation of b1 integrins [44]; type I collagen is used as a
supporting material in order to allow leukocytes to survive and
proliferate. Bacterial cell sonicates were added to each well at an
equivalent concentration to an MOI of 30 and cells were cultured
for 5 days at 37uC with 5% CO2. After 5 days leukocytes were
liberated from the collagen gel by the addition of collagenase
(1000 U/ml). Cells were washed and counted before RNA
extraction.
RT-qPCR
RNA was extracted from the cultured leukocytes using a
Macherey-Nagel NucleoSpin RNA II Isolation Kit (ABgene,
Epsom, UK). Synthesis of cDNA was carried out using 500 ng of
random hexamers using the ImProm-II Reverse Transcription
System (Promega) in a final volume of 20ml. All reactions were
prepared according to the manufacturer’s instructions giving a
final magnesium chloride concentration of 3 mM. All cDNAs were
diluted to a final volume of 100ml (1/5 dilution) using EB buffer
(10 mM Tris HCl pH 8.4; Qiagen Ltd., Crawley, UK). Primers
and probes were designed using Primer 3 (http://frodo.wi.mit.
edu/primer3) and M-Fold using the human specific GenBank
sequences for T-box21 (accession number NM_013351), GATA-3
(accession number NM_001002295), RORC (accession number
NM_005060), Foxp3 (accession number NM_017009), IFNc
(accession number NM_000619), TNFa (accession number
NM_000594), IL-4 (accession number NM_000589), IL-4d2
(accession number NM_172348), IL-17A (accession number
NM_002190), IL-10 (accession number NM_000572) and TGFb
(accession number NM_000660). The housekeeper gene hydro-
xymethylbilane synthase (HMBS) was used as an internal control.
Quantitative PCR (qPCR) was performed using HotStarTaq
Master Mix (Qiagen Ltd.). Gene specific amplification was
performed using 0.2mM of each primer, 0.1mM of probe or SYBR
Green 1 (1/100,000; Sigma) and 5ml of diluted cDNA in a final
Iron Responsive Candidate Probiotic
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to 4.5 mM in the final reaction by addition of 50 mM MgCl2.
Sample incubations were performed in an MxPro3005P (Strata-
gene, California, USA) at 95uC for 15 minutes and then 45 cycles
of 95uC for 15 seconds, and 60uC for 30 seconds during which the
fluorescence data were collected. Data is expressed as the relative
change in mRNA transcription following treatment and is
normalised for cell number. No significant differences were seen
between cells isolated from the three disease states and therefore
results were pooled for analysis. Differences were analysed using
paired t-tests (GraphPad Prism 5).
Supporting Information
Figure S1 Effect of probiotic on TEER in T84 (A) and
Caco-2 cells (B). *p #0.05, ** p#0.01 and *** p#0.001.
(TIF)
Figure S2 Percent change in cytokine mRNA levels in
response to E. coli with and without probiotic. Results are
expressed as mean6S.E.M. * p#0.05.
(TIF)
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